COMMUNIQUÉS West-GlobeNewswire

CORXEL Receives Study May Proceed Letter from the U.S. FDA for the Phase 2 Trial of CX11 in Patients with Obesity and Overweight Conditions
15/04/2025
The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemes The trial is expected to enroll 250 patients to receive treatment over 36 weeks BERKELEY HEIGHTS [...]
Galapagos Announces Departure of Thad Huston, CFO and COO, as of August 1, 2025
15/04/2025
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through [...]
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
15/04/2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational Highlights Direct MagnetOs [...]
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
15/04/2025
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting [...]
Communiqué de presse : Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO
15/04/2025
Le portefeuille de traitements contre les maladies respiratoires de Sanofi s’enrichit de nouvelles données sur l’asthme et prévoit de nouvelles études cliniques sur la BPCO De nouvelles données de phase II démontrent l’ [...]
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
15/04/2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”
15/04/2025
Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and [...]
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
15/04/2025
LA JOLLA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results
14/04/2025
- Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Quality NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- [...]
BioSyent to Attend Planet MicroCap Showcase
14/04/2025
MISSISSAUGA, Ontario, April 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las [...]
Cue Biopharma Announces Proposed Public Offering
14/04/2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Cue Biopharma to Host Business Update Call and Webcast
14/04/2025
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Aurora Spine Announces the Resignation of Board Director James Snow
14/04/2025
CARLSBAD, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal [...]
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
14/04/2025
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in- [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/04/2025
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven [...]
TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2024 Financial Results
14/04/2025
FREDERICK, Md., April 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization [...]
Voting Rights and Shares Capital of the Company
14/04/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 14, 2025 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
14/04/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 avr. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
14/04/2025
Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share, [...]

Pages